Solid Q3 favours a fifth guidance upgrade later this year M&A and strong '25 guidance trigger positi...
Plejds nettoomsättning för det tredje kvartalet 2024 uppgick till 153,1 MSEK (119,9), en ökning med ...
Redeye comments on Annexin's Q3 report and recent events in the company, most notably the top-line d...
Vaisala reports its Q3/24 results on Thursday 24th of October.
Redeye states that Q3 numbers aligned well with our expectations.
Sales -12% and adj. EBIT SEK -4m vs. ABGSCe Lower volumes from some large customers likely temporary...
Redeye provides a comment on Safeture’s Q3 2024 report, which showed ARR growth of 16% and sales gro...
Hansa delivers a healthy increase in patients using IDEFIRIX.
Redeye is only making minimal changes to our forecasts on the back of the Q3 report.
Redeye updates its estimates ahead of Arise’s Q3 report which is due on 7 November.
The recent period of strong revenue growth may have come to an end in Q2, as we expect negative reve...
Q3e: Medical stable, cyclical risk in Engineered Estimates lowered by 2% p.
Expect continued softness on orders, comps ease from Q4 Reduce '24e-'26e EBITA by 5-3% on delayed de...
Umida Group AB (”Umida”, ”koncernen” eller ”bolaget”) meddelade den 17 oktober år 2024 utfallande av...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) meddelade den 16 oktober år 202...
